The Manufacturers Life Insurance Company Has $9.24 Million Position in Sanofi (NASDAQ:SNY)

The Manufacturers Life Insurance Company lifted its holdings in Sanofi (NASDAQ:SNY) by 408.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 160,339 shares of the company’s stock after buying an additional 128,811 shares during the period. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $9,244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of SNY. Northwest Investment Counselors LLC purchased a new stake in Sanofi in the 3rd quarter worth approximately $29,000. POM Investment Strategies LLC acquired a new stake in Sanofi during the second quarter valued at $25,000. Concord Wealth Partners grew its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new position in Sanofi in the 2nd quarter worth about $35,000. Finally, Fortitude Family Office LLC raised its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 0.4 %

Sanofi stock opened at $48.17 on Wednesday. The firm has a market capitalization of $122.25 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 1.22 and a beta of 0.58. The company’s 50 day simple moving average is $52.61 and its 200 day simple moving average is $52.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter last year, the business posted $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sanofi will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on SNY shares. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.